Literature DB >> 17091543

Intraperitoneal chemotherapy for frontline ovarian cancer therapy: vindicated or vilified?

Robert L Coleman.   

Abstract

Entities:  

Year:  2006        PMID： 17091543     DOI： 10.1007/s11912-006-0072-y

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  4 in total

Review 1.  Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.

Authors:  K Jaaback; N Johnson
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

2.  Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.

Authors:  Joan L Walker; Deborah K Armstrong; Helen Q Huang; Jeffrey Fowler; Kenneth Webster; Robert A Burger; Daniel Clarke-Pearson
Journal:  Gynecol Oncol       Date:  2006-01       Impact factor: 5.482

3.  Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

Authors:  D S Alberts; P Y Liu; E V Hannigan; R O'Toole; S D Williams; J A Young; E W Franklin; D L Clarke-Pearson; V K Malviya; B DuBeshter
Journal:  N Engl J Med       Date:  1996-12-26       Impact factor: 91.245

4.  Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.

Authors:  M Markman; B N Bundy; D S Alberts; J M Fowler; D L Clark-Pearson; L F Carson; S Wadler; J Sickel
Journal:  J Clin Oncol       Date:  2001-02-15       Impact factor: 44.544
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.